BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33398536)

  • 1. Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.
    Oliva MA; Staffieri S; Castaldo S; Giangaspero F; Esposito V; Arcella A
    J Neurooncol; 2021 Jan; 151(2):123-133. PubMed ID: 33398536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHO 2016 Classification of gliomas.
    Wesseling P; Capper D
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):139-150. PubMed ID: 28815663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
    Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
    J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II.
    Karschnia P; Teske N; Dorostkar MM; Siller S; Weller J; Baehring JM; Dietrich J; von Baumgarten L; Herms J; Tonn JC; Thon N
    Sci Rep; 2020 Nov; 10(1):19758. PubMed ID: 33184319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Classification of Diffuse Gliomas.
    Kalidindi N; Or R; Babak S; Mason W
    Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
    Weller M; Reifenberger G
    Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between
    Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
    Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor enhances effect of temozolomide on high-grade glioma cells.
    Yang D; Cheng X; Bu X; Yan Z; Wu T; Zhang Y
    Anticancer Drugs; 2020 Oct; 31(9):950-958. PubMed ID: 32590393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas].
    Feiden S; Feiden W
    Pathologe; 2008 Nov; 29(6):411-21. PubMed ID: 18820922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14.
    Deng MY; Sill M; Sturm D; Stichel D; Witt H; Ecker J; Wittmann A; Schittenhelm J; Ebinger M; Schuhmann MU; Figarella-Branger D; Aronica E; Staszewski O; Preusser M; Haberler C; Lauten M; Schüller U; Hartmann C; Snuderl M; Dunham C; Jabado N; Wesseling P; Deckert M; Keyvani K; Gottardo N; Giangaspero F; von Hoff K; Ellison DW; Pietsch T; Herold-Mende C; Milde T; Witt O; Kool M; Korshunov A; Wick W; von Deimling A; Pfister SM; Jones DTW; Sahm F
    Neuropathol Appl Neurobiol; 2020 Aug; 46(5):422-430. PubMed ID: 31867747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
    Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
    Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.